Company ProfilePremium

Advik Laboratories Limited

Company Profile Analysis

Ticker: 531686.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Advik Laboratories Limited - Company showcase

Year Founded & Workforce

1994

18 Employees

Advik Laboratories Limited logo

Advik Laboratories Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Advik Laboratories Limited Overview

MPS Pharmaa Limited is a Haryana-incorporated, BSE-listed micro-enterprise that was built in the late 1990s and 2000s as Advik Laboratories, a generic formulations manufacturer producing tablets, capsules and dry syrups from a single plant at Sohna and exporting branded generics such as Zin-Ten into overseas markets. Revenue peaked at roughly INR 34 Cr in FY2013 and collapsed to near zero by FY2020 after the business lost scale, working capital and bank support. Since a July 2021 bank settlement funded by Vikas Lifecare, the company has been a dormant shell carrying the Sohna land, building and capital work-in-progress, about INR 7.5 Cr of borrowings and a net worth that had shrunk to INR 0.07 Cr by March 2026. Management's stated path back to operations is a pivot, approved in September 2025, into Ayurvedic, Unani, Homeopathic and nutraceutical manufacturing. Today it is best characterised as a turnaround option on a listed shell rather than an operating pharmaceutical company.


The company's own description

In its recent annual reports and exchange profiles the company describes itself as engaged in the manufacturing, marketing, trading and export of pharmaceutical products, operating its own manufacturing facility at Sohna, Haryana, and using independent contract/third-party manufacturers across India (Screener.in key points sourced to Annual Report FY2024, p.100). Its stated guiding philosophy is "Healthy People, Healthy Nation" (Groww company profile, derived from the annual report). Historically the portfolio covered ethical, generic and over-the-counter drugs across antibacterials, antiallergics, antifungals, analgesic/antipyretic/anti-inflammatory agents, antihypertensives, anthelmintics, antimalarials, corticosteroids, erectile-dysfunction products, gastrointestinal agents and sedatives (IIFL company summary).

The FY2025/FY2026 Management Discussion & Analysis adds a new strand: on 2 September 2025 the Board approved diversification into the manufacture of Ayurvedic, Unani and Homeopathic medicines, drugs and nutraceuticals, and appointed an Ayurvedacharya, Mr. Joshi, described as having over two decades of production, sales and marketing experience in Ayurvedic pharmaceuticals in Nepal and India (IIFL MD&A reproduction).

Independent characterisation

The stated description substantially overstates current activity. Reported revenue from operations was INR 2.33 lakh in FY2023, INR 9.37 lakh in FY2024 and INR 4.77 lakh in FY2025 (Directors' Reports FY2024 and FY2025), i.e. well under INR 0.1 Cr a year; Screener.in classifies these receipts as other income and shows sales of zero for FY2023–FY2026. Quarterly expenses have run at roughly INR 0.18–0.21 Cr, covering staff, depreciation on the idle plant and listing/compliance costs, producing a steady annual loss near INR 0.9–1.0 Cr. The only revenue line visible in FY2026 is INR 3.56 lakh in Q4 FY2026, which was booked against a cost of revenue of INR 15.4 lakh (Google Finance), consistent with sale of residual inventory or a trial batch rather than an operating business.

Business and revenue model

DimensionHistorical model (FY2005–FY2015)Current state (FY2020–FY2027 YTD)
Revenue modelProduct sales of finished dosage formulations (generic and branded generic); exports; some tradingEffectively nil; incidental receipts only
Product vs service mix~100% productNot meaningful
Value-chain positionFormulator (buys APIs, manufactures tablets/capsules/dry syrups); supplemented by third-party manufacturingPlant idle; workforce cut by 10 in April 2026
Customer typesDomestic distributors/stockists; institutional buyers; overseas importers (e.g., Qmedic order, Max Medical UK tie-up in 2003)None disclosed
End marketsIndia domestic formulations; export markets (UK/Europe and other regions via partners)Planned: AYUSH (Ayurveda/Unani/Homeopathy) and nutraceuticals
Licensing / subscription——

Strategy

Stated strategy

The only articulated strategy in recent disclosures is the AYUSH and nutraceutical diversification. The Board approved it on 2 September 2025, and the MD&A of the FY2025 and FY2026 annual reports reiterates it. Management's themes, paraphrased from the MD&A, are:

  1. Shift to natural healthcare: Enter the manufacture of Ayurvedic, Unani and Homeopathic medicines and nutraceuticals in response to consumer demand for natural and holistic health solutions.

  2. Government support and global recognition: Management cites policy support for traditional medicine systems and their growing acceptance internationally as tailwinds.

  3. Domain expertise: Use the appointed Ayurvedacharya's experience in production, sales and marketing in India and Nepal to build the new business across manufacturing and trading of Ayurvedic, herbal, Unani, nutraceutical and allopathic products.

  4. Workforce realignment: Retrench existing factory staff whose skills do not match the new production requirements (March 2026).

The MD&A also contains generic industry commentary, for example a projection that India's biosimilars market would grow at about 22% CAGR to USD 12 billion by 2025. This commentary has no evident link to the company's own plans.

Initiative register (last 24 months)

DateInitiativeDetailTarget / budgetStatus
2 Sep 2025AYUSH and nutraceutical diversificationBoard approval of new line of business—Planning; no licence, capex or launch disclosed
2 Sep 2025Appointment of Ayurvedacharya Mr. JoshiDomain lead for the new business—Done
29 Sep 2025Governance: five-year secretarial auditor appointmentCompliance with amended LODR Regulation 24A—Done
3 Mar 2026Workforce retrenchment10 factory workers, effective 2 Apr 2026Cost savings not quantifiedDone
28 May 2026Internal auditSanghi & Co. considered for FY2027 internal audit—Approved (per agenda)
29 Sep 2026Board strengtheningIndependent director appointment; auditor (re)appointment—Done

Medium-term financial targets or guidance: None publicly disclosed.

ESG commitments: None disclosed.

Cost programme: None formally announced beyond the retrenchment.

Funding plan: No fund-raising (rights issue, preferential allotment or debt) has been announced to finance the pivot. This is the most important missing piece.

Products & Services

The company does not publish a current product catalogue, and with revenue near zero there is no evidence that any brand is presently being sold in commercial quantity. The catalogue below reconstructs the historical portfolio from disclosures and should be read as legacy, not current.

Dosage forms

Dosage formDescriptionStatus
TabletsConventional oral solid dosage manufactured at SohnaLegacy; plant idle
CapsulesHard-gelatin capsulesLegacy
Dry syrupsPowder for oral suspension (typically antibiotics/paediatric)Legacy

Named brands

BrandCategoryLaunch / reference yearTarget customerPricingStatus
Zin-TenAnti-allergic tabletsEstablished overseas FY2003-04Export markets—Legacy; no current sales disclosed
BiosulfDescribed as a biotech product2,003——Legacy
EnervaRange in various strengths (therapeutic class not disclosed)2,003——Legacy

Therapeutic categories (generic portfolio, historical)

CategoryExample indicationStatus
AntibacterialsInfectionsLegacy
AntiallergicsAllergic rhinitis, urticariaLegacy
AntifungalsFungal infectionsLegacy
Analgesic / antipyretic / anti-inflammatoryPain, fever, inflammationLegacy
AntihypertensivesHypertensionLegacy
AnthelminticsWorm infestationsLegacy
AntimalarialsMalariaLegacy
CorticosteroidsInflammatory conditionsLegacy
Erectile-dysfunction agentsEDLegacy
Gastrointestinal agentsAcid-peptic and GI disordersLegacy
SedativesAnxiety/insomniaLegacy

Source: IIFL company summary; Twelve Data and EMIS profiles (EMIS also lists anti-allergic and anti-inflammatory capsules/tablets and antihypertensives).

Planned portfolio (announced 2 September 2025)

Planned lineDescriptionLaunch dateStatus
Ayurvedic medicinesClassical and proprietary Ayurvedic formulations—Planning; no AYUSH manufacturing licence disclosed
Unani medicinesUnani formulations—Planning
Homeopathic medicinesHomeopathic formulations—Planning
NutraceuticalsHealth supplements—Planning
Herbal and allopathic tradingMD&A references manufacturing and trading of herbal and allopathic drugs alongside AYUSH—Planning

No product names, capacities, capital expenditure budgets, licences or launch timetables for the new lines have been disclosed as of October 2026.

Financial Narrative

All figures standalone, INR Cr, fiscal years ending 31 March, from Screener.in reproductions of BSE-filed results unless noted. Derived ratios are calculated by the analyst from those figures.

Income statement

Notes: (1) Revenue discrepancy — the Directors' Reports show small "revenue from operations" (FY2023 INR 2.33 lakh; FY2024 INR 9.37 lakh; FY2025 INR 4.77 lakh), which Screener.in appears to classify within other income; both are shown. FY2026 revenue is the Q4 figure (Google Finance). (2) The Directors' Report figures for loss before depreciation (FY2025 INR 71.71 lakh; FY2024 INR 70.66 lakh; FY2023 INR 92.52 lakh) reconcile with the derived EBITDA row. (3) FY2022 net loss was cushioned by a tax credit (effective rate −85%), and FY2022 depreciation was higher before the depreciable base shrank. (4) Diluted EPS equals basic; no dilutive instruments are disclosed. (5) Gross profit is not reported annually; in Q4 FY2026 cost of revenue of INR 15.4 lakh exceeded revenue of INR 3.56 lakh, a gross loss of about INR 11.8 lakh (Google Finance).

Margins and growth

Gross, operating and EBITDA margins are not meaningful (revenue negligible). Value Research shows a TTM net margin of −2,886%. Five-year revenue CAGR is not meaningful; on Screener's ten-year series sales fell from INR 12.24 Cr (FY2015) to zero.

Commentary. The income statement describes a cost base without a business. Annual expenses have been stable at INR 0.7–1.0 Cr since FY2022, and with no gross profit to absorb them the company has lost INR 0.8–1.1 Cr before tax every year. The FY2026 loss widened by about 22% because Q4 FY2026 expenses roughly doubled to INR 0.37 Cr. The likely causes are retrenchment compensation for the 10 workers (approved 3 March 2026) and the cost of the Q4 trial sale; the breakdown is not disclosed. The absence of any finance cost despite INR 7.5 Cr of borrowings is notable. Screener's automated checks flag possible interest capitalisation; the alternative explanation is that the borrowings are interest-free loans from related or promoter-linked parties.

Quarterly trend (last five quarters)

Source: Screener.in quarterly results (BSE filings). Q4FY2026 "other income" of INR 0.04 Cr corresponds to the INR 3.56 lakh revenue reported elsewhere.

Balance sheet

Notes: Cash and equivalents are not separately shown by Screener; net cash flow has been approximately zero every year, implying a minimal cash balance. The short-/long-term split of borrowings is not disclosed in retrievable sources; the company disclosed borrowings of INR 7.46 Cr as at 31 March 2025 in its "Large Corporate" non-applicability filing (Screener.in announcements, 2025). Goodwill and intangibles are not reported (none disclosed). Net debt is approximately equal to gross borrowings given negligible cash. Working capital is not reported directly; other assets less other liabilities was approximately INR 0.98 Cr at FY2026 (derived, excluding any current portion of borrowings). Upstox reports a current ratio of 3.06 (period not stated).

Implied current position. After the Q1 FY2027 loss of INR 0.24 Cr, shareholders' equity of INR 0.07 Cr at 31 March 2026 implies a negative net worth of roughly INR −0.17 Cr at 30 June 2026 (analyst derivation; the half-year balance sheet to 30 September 2026 was not yet published at the time of research).

Cash flow

Capex is not separately disclosed. Positive investing flows in FY2024–FY2026, alongside a falling CWIP balance (INR 3.40 Cr to INR 2.41 Cr), suggest that capital work-in-progress or other assets were being realised or written down rather than invested in.

Commentary. FY2022 was the restructuring year. Operating outflow of INR 4.34 Cr, which reflects settlement of legacy bank and trade liabilities, was funded by INR 3.88 Cr of new financing, consistent with Vikas Lifecare's announced bank settlement. Since then the company has burned INR 0.6–0.9 Cr a year from operations. That burn has been funded by a shrinking mix of fresh borrowing (financing inflow fell from INR 0.96 Cr in FY2023 to INR 0.07 Cr in FY2026) and realisation of investing assets (INR 0.38 Cr in FY2025 and INR 0.52 Cr in FY2026). The pattern suggests the company is drawing on its remaining asset base rather than receiving new lender or promoter money, which cannot continue indefinitely. CWIP of INR 2.41 Cr is now the largest liquid-in-principle asset.

Ratios

Not meaningful (NM): ROIC (negative NOPAT on a near-zero equity base), net debt/EBITDA (negative EBITDA), interest coverage (no reported interest expense; Screener nonetheless flags low coverage), cash conversion cycle (no trade revenue; Screener's last computed CCC was 3,504 days in FY2022). The Screener and Value Research ROE figures (−177% FY2026; three-year average −61%) match the analyst's derivation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Pharmaceuticals revenue from operations (INR Lakh)

9.374.773.56

Pharmaceuticals pre-tax result (INR Cr)

-0.86-0.87-1.06

Share of total revenue (%)

100100100

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Sales per Screener (INR Cr)

0.030.000.000.000.00

Revenue from operations per Directors' Report (INR Lakh)

—2.339.374.773.56

Total expenses (INR Cr)

0.710.950.800.770.95

Operating profit (INR Cr)

-0.68-0.95-0.80-0.77-0.95

Other income (INR Cr)

0.260.020.090.050.04

EBITDA (INR Cr, derived)

-0.42-0.93-0.71-0.72-0.91

Depreciation (INR Cr)

0.510.150.150.150.15

Interest expense (INR Cr)

0.000.000.000.000.00

Pre-tax income (INR Cr)

-0.93-1.08-0.86-0.87-1.06

Net income (INR Cr)

-0.14-1.05-0.83-0.90-1.02

EPS basic (INR)

-0.07-0.55-0.43-0.47-0.53

EPS diluted (INR)

-0.07-0.55-0.43-0.47-0.53

Dividend per share (INR)

00000

Margin Analysis (%)

MetricFY2023FY2024FY2025FY2026

Net margin on directors'-report revenue (%)

-4,506-886-1,887-2,865

Pre-tax loss YoY change (%)

16-20122

Income Statement and Per-Share Data (Quarterly)

MetricQ1FY2026Q2FY2026Q3FY2026Q4FY2026Q1FY2027

Sales (INR Cr)

0.000.000.000.000.00

Expenses (INR Cr)

0.190.190.190.370.20

Other income (INR Cr)

0.000.000.000.040.00

Depreciation (INR Cr)

0.040.040.040.040.04

Pre-tax income (INR Cr)

-0.23-0.23-0.23-0.37-0.24

Net income (INR Cr)

-0.22-0.22-0.22-0.36-0.24

EPS (INR)

-0.12-0.12-0.12-0.19-0.13

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr)

19.1119.1119.1119.1119.11

Reserves (INR Cr)

-15.29-16.32-17.14-18.03-19.04

Shareholders' equity (INR Cr)

3.822.791.971.080.07

Total borrowings (INR Cr)

5.816.777.277.467.52

Other liabilities (INR Cr)

0.530.630.700.800.88

Total assets (INR Cr)

10.1610.199.949.348.47

Net fixed assets (INR Cr)

4.174.144.013.833.66

Capital work-in-progress (INR Cr)

3.423.403.262.912.41

Investments (INR Cr)

0.540.540.540.540.54

Other assets incl. cash (INR Cr)

2.032.112.132.061.86

Book value per share (INR)

2.001.461.030.570.04

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

-4.34-0.87-0.63-0.57-0.59

Investing cash flow (INR Cr)

0.46-0.100.120.380.52

Financing cash flow (INR Cr)

3.880.960.510.180.07

Net cash flow (INR Cr)

0.00-0.010.000.000.00

Free cash flow per Screener, CFO plus CFI (INR Cr)

-3.88-0.97-0.51-0.19-0.07

Dividends paid (INR Cr)

00000

Buybacks (INR Cr)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

-3.6-31.8-34.9-59.0-177.4

ROA on year-end assets (%)

-1.4-10.3-8.4-9.6-12.0

ROCE per Screener (%)

-9.66-11.26-9.15-9.79-13.14

Debt to equity (x)

1.522.433.696.91107.43

Asset turnover on directors'-report revenue (x)

—0.0020.0090.0050.004

Revenue by Region

MetricFY2024FY2025FY2026

Total revenue from operations, all geographies (INR Lakh)

9.374.773.56

Valuation Snapshot

MetricValueSource

Last price

INR 2.08

Screener.in

52-week high / low

INR 2.08 / INR 1.57

Screener.in

Market capitalisation

INR 3.98 Cr

Screener.in

Enterprise value (derived: market cap + borrowings INR 7.52 Cr, cash negligible)

≈INR 11.5 Cr

Analyst derivation

Average daily volume

≈487 shares

Google Finance

Surveillance

BSE GSM framework

Trendlyne

Share Price & Returns

PeriodReturnSource

1 year

≈0% (Screener); −2.45% to 28 Aug 2026 and +4.52% to 21 Sep 2026 (Anand Rathi)

Screener.in; Anand Rathi

3 years

−8% CAGR (Screener); about −18% cumulative to 21 Sep 2026 (Anand Rathi)

Screener.in; Anand Rathi

5 years

+11% CAGR

Screener.in

10 years

−9% CAGR

Screener.in

Valuation Multiples

MultipleMPS PharmaaPeer reference

P/E (TTM)

NM (EPS INR −0.56 TTM)

Industry P/E ≈44.6 (Groww)

EV/EBITDA

NM (EBITDA negative; Upstox shows −14.2x)

—

EV/Sales

≈320x on FY2026 revenue of INR 0.036 Cr (derived)

—

P/B

≈57x on book value INR 0.04 (Screener)

Peer median ≈3.8x (Value Research)

Dividend yield

0%—

Analyst Conclusions

Management guidance and consensus

No financial guidance has been issued. Management's only forward-looking statement is qualitative: the MD&A describes the outlook for Ayurvedic, Unani, Homeopathic and nutraceutical manufacturing as highly positive. There are no consensus estimates.

Bull case

  1. Asset backing exceeds market value. Net fixed assets of INR 3.66 Cr plus CWIP of INR 2.41 Cr and investments of INR 0.54 Cr (INR 6.61 Cr at book) exceed the INR 3.98 Cr market cap. If the Sohna site is worth near book, equity holders retain option value even after INR 7.52 Cr of debt, provided lenders are patient or the debt converts into equity.

  2. Low-cost re-entry into a growing category. An existing industrial site with a pharma GMP heritage, a cash burn below INR 0.6 Cr a year and an experienced Ayurvedacharya could allow contract AYUSH and nutraceutical manufacturing to start with modest capex.

  3. Recapitalisation or change-of-control catalyst. A stable 35.89% promoter block, a 17.51% strategic block last held by Vikas Lifecare and a clean listing make the company a candidate for preferential allotment, debt-to-equity conversion or reverse merger. Any such announcement would likely re-rate a stock this illiquid.

Bear case

  1. Equity has already been wiped out on book. Net worth went from INR 3.82 Cr (FY2022) to INR 0.07 Cr (FY2026) and was implied negative after Q1 FY2027. At the current loss rate of about INR 1 Cr a year, the deficit deepens annually while borrowings rank ahead of equity.

  2. Thirteen months after approval, the pivot has nothing to show. There is no licence, capex, product, customer or funding. The only concrete action has been retrenching 10 workers, which cuts costs but also capability.

  3. Auditor qualifications, GSM surveillance and illiquidity. Average volume of about 487 shares a day, and a P/B of about 57x on a near-zero book value, mean the quoted price is a weak signal of value and exits are difficult.

Key catalysts and monitorables (next 12 months)

MonitorableWhy it mattersExpected timing
H1 FY2027 balance sheet (results due by mid-November 2026)Confirms whether net worth has turned negativeNov 2026
Identity and terms of lenders (FY2026 annual report notes)Determines insolvency risk and whether debt could convert to equityAvailable now (annual report)
Text of FY2026 audit report: qualification or going-concern languageSignals auditor view of viabilityAvailable now
AYUSH manufacturing licence or contract-manufacturing agreementFirst tangible evidence of the pivotAny time
Fund-raising announcement (preferential issue, capital reduction, rights issue)Required to fund any restartAny time
Changes in the Vikas Lifecare stake or promoter holdingSignals change of control or a strategic exitQuarterly shareholding filings
Quarterly expense run-rate after retrenchmentTests whether costs drop below about INR 0.19 Cr per quarterQ2–Q4 FY2027
GSM status and any exchange actionLiquidity and listing riskOngoing

Analyst verdict

MPS Pharmaa Limited, the former Advik Laboratories, is not an operating pharmaceutical company in any meaningful sense, and it should not be analysed as one. Sales collapsed from INR 33.86 Cr in FY2013 to effectively nil by FY2020, and every year since has produced a near-identical loss of about INR 1 Cr, funded first by new borrowing and more recently by running down capital work-in-progress. Five years of this pattern have reduced shareholders' equity from INR 3.95 Cr to INR 0.07 Cr. On a straightforward roll-forward of the June 2026 quarter's loss, equity is now negative, while INR 7.52 Cr of borrowings sit ahead of shareholders.

The September 2025 decision to pivot into Ayurvedic, Unani, Homeopathic and nutraceutical manufacturing is directionally sensible. It points a dormant, GMP-heritage site in the NCR industrial belt towards a category with supportive policy and rising consumer interest. But a strategy is only as credible as its funding, and the company has disclosed none: no capex budget, no licence, no partner and no capital raise. The one concrete step, retrenching ten factory workers, lowers costs but also strips out operating capacity.

The equity is therefore best understood as a low-probability option on one of three outcomes: a credible recapitalisation that funds the AYUSH conversion; a change of control that uses the listed shell; or monetisation of the Sohna site at a value above the debt. Against that option stand a negative book value, recurring audit qualifications, GSM surveillance and trading so thin that the quoted price of about INR 2 conveys little information. For institutional purposes the stock is uninvestable on fundamentals. It merits monitoring only for a discrete corporate event. The two documents that would most change this view are the FY2026 audit report's going-concern language and the lender disclosures in the FY2026 notes to accounts.


Principal sources consulted

  • BSE corporate filings for scrip 531686: Annual Reports FY2016, FY2019, FY2021, FY2023, FY2024 (cover letters and notices); board meeting outcome dated 2 Sep 2024; AGM outcome dated 29 Sep 2025.

  • Screener.in company page for 531686: P&L, balance sheet, cash flow, ratios and quarterly results FY2015–Q1 FY2027; shareholding to Sep 2026; announcements to 10 Oct 2026; price as of 12 Oct 2026.

  • IIFL (indiainfoline.com): company summary; Directors' Reports FY2024 and FY2025; MD&A; board-meeting corporate actions.

  • Business Standard / Capital Market, "Vikas Lifecare acquires 22.04% stake in Advik Laboratories", 14 Jul 2021.

  • Scanx: retrenchment disclosure (3 Mar 2026); independent directors' meeting (16 and 25 Mar 2026); Q4 FY2026 investor complaints. Reuters brief via Zerodha (retrenchment).

  • Simply Wall St (S&P Global Market Intelligence data, May 2025): management and board tenure.

  • Value Research; Upstox; Groww; Google Finance; TradingView; Trendlyne; Pocketful; Bajaj Finserv; Anand Rathi; ICICI Direct; Angel One; Equitymaster; EMIS; Twelve Data: market data, history and peer comparisons.

  • Medical Dialogues (3 Dec 2025): industry context on nutraceutical M&A.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenure (approx.)Background / other rolesAgeFY2026 compensation

Peeyush Kumar Aggarwal

Chairman, Managing Director, Executive Director, Promoter

Board ≈11.8 yrs and CEO ≈7.2 yrs as of May 2025 (Simply Wall St), implying board entry ≈2013 and MD role ≈2018

Managing Director & Executive Director of B. P. Capital Limited from 9 Feb 2024 and previously its chairman

61 (as of 2025)

Not publicly disclosed in retrieved sources

Madhu Sharma

Independent, Non-Executive Director

≈10.7 yrs (as of May 2025)

——

Sitting fees not disclosed

Ram Niwas Sharma

Non-Executive, Non-Independent Director

≈5.8 yrs (as of May 2025)

———

Ajay Sharma

Independent, Non-Executive Director (initially Additional Director)

≈1.8 yrs (as of May 2025)

———

Independent director appointed at 32nd AGM

Independent Director

From 29 Sep 2026

———

Pooja Chuni

Company Secretary & Compliance Officer

————

Chief Financial Officer

CFO

————

Mr. Joshi (Ayurvedacharya)

Appointed in connection with AYUSH diversification (exact designation not disclosed)

From 2 Sep 2025

Over 20 years in Ayurvedic production, sales and marketing in Nepal and India

——

“—” = not publicly disclosed.

Major Shareholders

Shareholder categorySep 2026 stake (%)Source

Promoters & promoter group

35.89

Screener.in shareholding (BSE)

Domestic institutions (DIIs)

0.58

Screener.in

Foreign institutions (FIIs)

0.00

Anand Rathi; Screener.in

Public / non-institutional

63.53

Screener.in

Number of shareholders

4,395

Screener.in

Named holder

Stake (%)

Date / basis

Vikas Lifecare Ltd

17.51—

Peeyush Kumar Aggarwal

≈10.24

S&P Global data, May 2025

Unnamed DII

0.58

Since Dec 2024

Competitive Landscape

Competitors by Segment

SegmentCompetitorListed?Comparative data available hereRelative positioning vs MPS Pharmaa

Generic formulations (historical)

FDC Ltd

Yes

FY2024 revenue ≈INR 1,942 Cr; PAT INR 305 Cr; net margin 15.7% (derived from Equitymaster per-share data)

Scale incumbent

Generic formulations (historical)

Pfizer Ltd (India)

Yes

FY2024 revenue ≈INR 2,193 Cr; PAT INR 551 Cr; net margin 25.1% (derived from Equitymaster)

MNC branded generics

Formulations / CDMO

Emcure Pharmaceuticals

Yes

Revenue INR 9,683 Cr; net profit INR 1,019 Cr; net margin 10.5% (Value Research, TTM)

Large-cap formulator

APIs / CDMO

Neuland Laboratories

Yes

Revenue INR 2,372 Cr; net profit INR 498 Cr; net margin 20.7% (Value Research)

Specialist API maker

APIs

Alivus Life Sciences

Yes

Revenue INR 2,590 Cr; net profit INR 603 Cr; net margin 22.6% (Value Research)

API maker

Fermentation APIs

Concord Biotech

Yes

Revenue INR 1,108 Cr; net profit INR 270 Cr; net margin 23.3% (Value Research)

Niche biotech API

Speciality intermediates

Ami Organics

Yes

FY2023 PAT INR 83 Cr; net margin 13.5% (Equitymaster)

Mid-cap chemicals/pharma

Ayurveda / AYUSH (prospective)

Dabur India

Yes

—

Category leader in Ayurvedic OTC

Ayurveda / AYUSH (prospective)

Emami (Zandu)

Yes

Not researched

Ayurvedic brands

Ayurveda / AYUSH (prospective)

Patanjali Ayurved; Himalaya Wellness; Shree Baidyanath; Charak Pharma

Mostly unlisted

Not publicly comparable

Scale brands with distribution

Unani (prospective)

Hamdard Laboratories (India)

No

Not publicly comparable

Unani category leader

Nutraceuticals (prospective)

Multinational and Indian supplement brands

Mixed

Not researched

Crowded, brand-driven

Peer Comparison FY2026

MetricMPS PharmaaEmcure PharmaNeuland LabsAlivus Life Sciences

Market cap (INR Cr)

438,24129,34917,570

Revenue (INR Cr)

0.049,6832,3722,590

Net profit (INR Cr)

-1.041,019498603

Net margin (%)

-2,88610.520.722.6

Revenue growth

—

Not researched

Not researched

Not researched

R&D intensity

—

Not researched

Not researched

Not researched

“—” = not publicly disclosed.

Company Snapshot

18

Employees

1994

Founded

District Mewat, India

Headquarters

SWOT Analysis

Strengths

  • Owned manufacturing site. The Sohna plant (138 Roz-Ka-Meo Industrial Area) carries net fixed assets of INR 3.66 Cr and CWIP of INR 2.41 Cr at FY2026 book (Screener.in), which is more than the INR 3.98 Cr market cap.
  • Regulatory heritage. The plant achieved WHO-GMP and ISO 9001:2008 certification in 2008 (Pocketful), so the site has a history of pharma GMP operations.
  • Clean listing infrastructure. Dual listing on BSE and ASE, about 4,395 shareholders (Sep 2026), and consistent statutory filings including nil investor complaints for every recent quarter (BSE filings, Apr 2025–Oct 2026).
  • Stable promoter base. Promoter holding has been unchanged at 35.89% since at least March 2017, with no evidence of promoter selling (Screener.in).
  • Low fixed cash burn. The operating cash outflow was only INR 0.57–0.63 Cr a year in FY2024–FY2026 (Screener.in), which keeps funding needs small in absolute terms.
  • Domain hire for the pivot. An Ayurvedacharya with more than 20 years of AYUSH industry experience was appointed on 2 Sep 2025 (IIFL MD&A).

Weaknesses

  • No revenue. Revenue from operations was INR 4.77 lakh in FY2025 and about INR 3.56 lakh in FY2026, versus INR 33.86 Cr in FY2013 (Directors' Report; Screener.in).
  • Eroded equity. Net worth fell from INR 3.82 Cr (FY2022) to INR 0.07 Cr (FY2026) and was implied negative after Q1 FY2027 (Screener.in; analyst derivation).
  • Leverage. Borrowings rose to INR 7.52 Cr against equity of INR 0.07 Cr, a debt/equity of 107x at FY2026 (Screener.in).
  • Persistent losses. The company has made a net loss every year since FY2015; the FY2026 loss was INR 1.02 Cr (Screener.in).
  • Governance concentration. The Chairman is also the MD and a promoter, and he is concurrently MD of B. P. Capital Ltd (Simply Wall St).

Opportunities

  • AYUSH and nutraceutical entry using the existing site, as approved by the Board on 2 Sep 2025 (IIFL).
  • Contract manufacturing for AYUSH brands, a capital-light route that does not require consumer brand-building, since the company historically used and understood third-party manufacturing models (Annual Report FY2024).
  • Equity recapitalisation. A preferential issue could restore net worth. Equity capital of INR 19.11 Cr at INR 10 face value against a trading price around INR 2 complicates pricing; issuance below par is generally not permitted, so capital reduction would likely need to precede it. This is an analyst observation, not a disclosed plan.
  • Asset monetisation. CWIP of INR 2.41 Cr and investments of INR 0.54 Cr could be realised to fund conversion, as investing inflows of INR 0.38 Cr (FY2025) and INR 0.52 Cr (FY2026) suggest is already happening (Screener.in).
  • Strategic investor entry. The listed shell, with a 35.89% promoter stake and a 17.51% block last held by Vikas Lifecare, could attract a reverse-merger or takeover interest (analyst inference).
  • Export of traditional medicines, building on the Ayurvedacharya's Nepal experience and the company's historical export relationships (IIFL MD&A; 2003 Max Medical/Qmedic history).

Threats

  • Insolvency or creditor action. With negative implied net worth and INR 7.5 Cr of borrowings, a creditor could seek IBC proceedings if loans were called (analyst assessment based on Screener balance sheet).
  • Regulatory hurdles. Converting an allopathic plant to AYUSH requires separate state AYUSH manufacturing licences and AYUSH GMP compliance (statutory framework); no licence has been disclosed after 13 months.
  • Exchange surveillance and liquidity. The stock is on BSE's GSM framework (Trendlyne), with average daily volume of about 487 shares (Google Finance), which limits any equity-raising options.
  • Competitive intensity. The AYUSH and nutraceutical markets are dominated by Dabur, Emami, Patanjali, Himalaya and others, and larger pharma companies are moving into nutraceuticals (Medical Dialogues, Dec 2025).
  • Execution capacity. A small board and limited staff following the April 2026 retrenchment make the restart difficult (Scanx).
  • Going-concern opinion. Auditor qualifications could escalate to a disclaimer or adverse going-concern opinion as equity turns negative (inference from FY2024–FY2025 qualifications).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
7 Apr 2025Stock hit a new 52-week low of INR 2.88 on heavy volume (Trendlyne)Start of a roughly 45% slide to INR 1.57 over the following year
16 Apr 2025Filed nil investor complaints statement, demat compliance certificate and Reg. 74(5) certificate for Q4 FY2025Routine compliance
Apr/May 2025Disclosed non-applicability of SEBI "Large Corporate" framework, with borrowings of INR 7.46 Cr at 31 Mar 2025Confirms debt level
May 2025FY2025 audited results: net loss INR 0.90 Cr; FY2025 revenue from operations INR 4.77 lakhFourth consecutive year of near-zero revenue
12 Aug 2025Board meeting for Q1 FY2026 results: net loss INR 0.22 CrRun-rate loss unchanged
2 Sep 2025Board approved diversification into Ayurvedic, Unani, Homeopathic medicines and nutraceuticals; appointed Ayurvedacharya Mr. Joshi; fixed AGM; recommended secretarial auditorOnly strategic initiative in years
29 Sep 202531st AGM: director re-appointment; secretarial auditor appointed for five consecutive yearsGovernance compliance
14 Nov 2025Q2 FY2026 results: net loss INR 0.22 CrNo revenue
Jan 2026Share price fell to about INR 1.68 (12 Jan 2026), down about 60% year-on-year per ICICI DirectMarket scepticism over the pivot
2 Feb 2026Q3 FY2026 results: net loss INR 0.22 CrNo revenue
3 Mar 2026Board approved permanent retrenchment of 10 factory workers at Sohna, effective 2 Apr 2026, citing the specialised skills needed for the AYUSH pivot (Reuters; Scanx)Wind-down of legacy operations; one-off cost hit in Q4
16 Mar 2026Scheduled separate independent directors' meetingGovernance compliance
25 Mar 2026Independent directors' meeting held for FY2026Review of non-independent directors and board information flow
2 Apr 2026Retrenchment effectiveRemaining headcount not disclosed
13 Apr 2026Nil investor complaints for Q4 FY2026Routine
11 May 2026Stock at INR 1.73; market cap INR 3.31 Cr; 52-week range INR 1.57–3.01 (Upstox)Near all-time-low valuation
28 May 2026FY2026 audited results: net loss INR 1.02 Cr; Q4 revenue INR 3.56 lakh against cost of revenue INR 15.4 lakh; agenda included auditor matters and internal auditor (Sanghi & Co.) for FY2027Loss widened by 13% YoY; net worth reduced to INR 0.07 Cr
Aug 2026Q1 FY2027 results: net loss INR 0.24 Cr, EPS INR −0.13Implies negative net worth from Q1 FY2027
Sep 2026FY2026 annual report filed with BSEPrimary source for the latest year
21 Sep 2026Share price at INR 2.08, up about 26% over six months (Anand Rathi)Rebound from lows, on thin volume
29 Sep 202632nd AGM approved accounts, director and auditor (re)appointments, appointment of an independent director, and related-party transactionsExpiry of auditor's four-year term addressed; related-party approval likely covers funding loans
1 Oct 2026Regulation 30 disclosures on change in directorate and auditor appointmentBoard and auditor changes formalised
7 Oct 2026Reg. 74(5) certificate for quarter ended 30 Sep 2026Routine
10 Oct 2026Nil investor complaints for Q2 FY2027Routine
12 Oct 2026Close of INR 2.08; market cap INR 3.98 Cr; P/B about 57x on a book value of INR 0.04Valuation detached from fundamentals

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Sales per Screener fell from INR 0.3 Mn in FY2022 to INR 0 Mn in FY2026.
Advik Laboratories Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Sales per Screener0.30000
Revenue from operations per Directors' Report—23.393.747.735.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.